STROKE - A POSSIBLE ADVERSE EFFECT OF COMBINATION THERAPY WITH PARITAPREVIR/RITONAVIR/OMBITASVIR + DASABUVIR. CASE REPORT

  • Egidia MIFTODE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R.S. MIFTODE “Sf. Spiridon” County Clinical Emergency Hospital Iasi
  • Lucia GRIGORE “Sf. Parascheva” Clinical Hospital of Infectious Diseases Iasi
  • S. TOADER “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Lidia-Oana STAMATEANU “Sf. Parascheva” Clinical Hospital of Infectious Diseases Iasi
  • Ionela-Larisa MIFTODE “Sf. Parascheva” Clinical Hospital of Infectious Diseases Iasi

Abstract

The development of direct-acting antiviral agents against hepatitis C virus has revolutionized the management and control of this important liver disease. Combination therapy with paritaprevir/ritonavir/ombitasvir + dasabuvir is considered one of the most effective and well-tolerated regimens used to treat chronic hepatitis C, with response rates over 95%. Ease of administration, excellent tolerance, and the absence of severe side effects have made treatment of chronic hepatitis C possible even in patients with severe fibrosis and in those with comorbidities. Insomnia, headache and fatigue are the most commonly reported side effects, the serious adverse events being uncommon. We will report a case of stroke as a possible serious adverse effect during treatment with paritaprevir/ritonavir/ombitasvir + dasabuvir (PrOD) in a 61-year-old male, former smoker, without cardiovascular history, in whom a conflict situation resulted in a hypertensive episode accompanied by paresthesia in the upper and lower right limbs, vertigo, equilibrium disorder, which turned out to be a stroke. Conclusions: Because the reported case may be a rare serious effect during the treatment with parita previr/ritonavir/ombitasvir + dasabuvir in a patient with hepatitis C virus (HCV) cirrhosis and without a cardiovascular history, careful neurological monitoring is recommended during this therapeutic regimen.

Author Biographies

Egidia MIFTODE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)
“Sf. Parascheva” Clinical Hospital of Infectious Diseases Iasi

S. TOADER, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (I)

References

1. El-Fishawy H, Saadi G, Hassaballa M, et al. Antiviral treatment prioritization in HCV infected patients with extrahepatic manifestations – an Egyptian perspective. J Adv Res 2016; 7: 391-402.
2. Majamudar A, Kitson MT, Roberts SK. Systematic review: Current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43: 1276-1292.
3. Wheeler-Singer A, Osinusi A, Brainard DM. Risk of cardiovascular and cerebrovascular events in hepatitis C patients fallowing completion of direct-acting antiviral therapy: a retrospective cohort study. J Hepatol 2017; 66(1): 282-283.
4. Zaid AM, Maher MM. Cerebrovascular accident; a possible serious adverse event of combined sofos-buvir-daclatasvir therapy: a case report. J Hepatol Gastroenterol 2017; 2(2): 1-4.
5. Kaneko R, Nakazaki N, Omori R, Yano Y, Ogawa M, Sato Y. Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. World J Hepatol 2018; 10: 88-94.
6. Smolders EJ, de Kanter CT, van Hoek B, et al. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and or renal impairment. Drug Saf 2016; 39: 589-611.
7. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017; 6: CD012143.
8. Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017; 96(50): e9271.
9. Saxena V, Khungar V, Verna EC, Levitsky J, Brown Jr RS, Hassan MA, Sulkowski MS, O’Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and Efficacy of Current Direct-Acting Antiviral Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results From the HCV-TARGET Study. Hepatology 2017; 66(4): 1090-1101.
10. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does Hepatitis C Virus Infection Increase Risk for Stroke? A Population-Based Cohort Study. PLoS ONE 2017; 7(2): e31527.
Published
2018-12-27
Section
INTERNAL MEDICINE - PEDIATRICS